Kite Pharma Inc. (KITE) 70.32 $KITE Critical Alerts For

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Kite Pharma Inc. (KITE) 70.32 $KITE

Critical Alerts For Palo Alto Networks, Intrexon, FireEye, Mylan and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PANW, XON, FEYE, MYL and KITE.
FEYE: 46.89 (+1.20), KITE: 70.32 (-1.59), XON: 59.83 (-0.77), MYL: 57.09 (+0.74), PANW: 182.40 (-4.43)

NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)

Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 35.46 (-0.85), BIIB: 310.86 (-9.07), BBC: 35.81 (-0.86), ADRO: 26.34 (-0.24), KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), TEVA: 71.10 (-0.31), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)

3 IPOs That Are Getting Strong Investor Attention
at Investor's Business Daily - Wed Jul 15, 11:48AM CDT
With strong investor demand for shares, ProNAi Therapeutics (DNAI) raised the expected price of its initial public offering, which is scheduled to price after the close Wednesday. ProNAi is among three of the eight IPOs out this week that are...
RPD: 24.61 (-0.41), CYBR: 58.28 (-1.55), KITE: 70.32 (-1.59), OLLI: 19.59 (-0.12), DNAI: 26.53 (-0.28), QLYS: 36.75 (-0.38), JUNO: 48.08 (-0.54)

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 96.01 (+0.72), FBT: 124.21 (-2.39), XBI: 251.67 (-7.27), AMGN: 169.92 (-2.82), IBB: 375.98 (-6.86), INTC: 29.03 (+0.07), CELG: 132.89 (-2.53), NFLX: 106.61 (-0.29), SPY: 210.27 (+0.94), GILD: 116.69 (+3.62), KITE: 70.32 (-1.59), RCPT: 227.77 (+0.61), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68), Z: 79.15 (-1.04)

Critical Alerts For Cliffs Natural Resources, JD.com, Kite Pharma, JetBlue and Amazon.com Released By InvestorsObserver
PR Newswire - Tue Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLF, JD, KITE, JBLU and AMZN.
AMZN: 527.05 (+1.02), KITE: 70.32 (-1.59), JBLU: 22.90 (+0.08), CLF: 2.89 (-0.08), JD: 32.92 (+0.44)

Trader's Notebook: Can Chevron Maintain Its High Yield?
at The Street - Tue Jul 14, 8:00AM CDT
Look under the hood when considering when to make a play for higher yielding names.
KITE: 70.32 (-1.59), CVX: 92.83 (+0.43)

5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.51 (-0.12), KITE: 70.32 (-1.59), GKOS: 32.10 (+1.33), AMRN: 2.21 (+0.06), CTCT: 24.79 (-0.42)

3 Biotech Stocks Working On CAR-T Immunotherapy You Ought To Watch
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 06, 12:02PM CDT
Source: Juno Therapeutics. Last week, Celgene Corp.  shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics ' stock and a handful of licensing rights, leaving Celgene with a 10% stake in the...
ZIOP: 12.45 (-0.19), KITE: 70.32 (-1.59), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)

InsiderInsights.com Daily Round Up 7/2/15: NHF, VISI, NXRT, ATLS
InsiderInsights - at Seeking Alpha - Sat Jul 04, 11:54AM CDT

LBTYK: 48.60 (-0.09), TACO: 15.37 (+0.03), ATLS: 3.32 (+0.25), GIII: 68.92 (-0.42), VISI: 9.50 (-0.12), NXRT: 12.73 (-0.08), ALRM: 17.75 (+0.67), TRU: 24.92 (+0.32), W: 36.13 (-1.73), LVLT: 49.41 (-3.09), PDVW: 29.05 (-1.37), COF: 79.11 (+0.46), KITE: 70.32 (-1.59), APPF: 14.52 (-0.18), CPLA: 51.24 (+0.99), HRG: 13.99 (+0.32), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04)

Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), ADMS: 25.23 (-1.31), ACHN: 8.41 (unch)

Celgene: The Juno Therapeutics Deal Is Worth The Premium
LN Investors - at Seeking Alpha - Wed Jul 01, 3:04PM CDT

KITE: 70.32 (-1.59), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53), NVS: 103.81 (+1.02)

Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
GlobeNewswire - Wed Jul 01, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
KITE: 70.32 (-1.59)

'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
at The Street - Wed Jul 01, 4:00AM CDT
The trading panel discussed Puerto Rico, European stocks and whether Facebook will buy Twitter.
FIT: 44.66 (-0.81), SPY: 210.27 (+0.94), NKE: 114.39 (+0.92), KITE: 70.32 (-1.59), GILD: 116.69 (+3.62), FB: 96.01 (+0.72), DB: 33.46 (+0.22), GOOGL: 654.47 (-5.19), KORS: 39.59 (+0.17), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68)

Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), CLLS: 35.73 (-0.65), JUNO: 48.08 (-0.54), CYAD: 57.09 (+0.25), CELG: 132.89 (-2.53)

Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)

A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)

Why Juno Therapeutics Stock Soared Today
George Budwell, The Motley Fool - Motley Fool - Tue Jun 30, 10:35AM CDT
What : Shares of the clinical-stage biopharma Juno Therapeutics jumped by 33% on exceptionally high volume today after the company announced a 10-year licensing agreement with Celgene Corp. for its CAR-T and TCR drug development platform. Per...
NBL: 36.08 (+0.58), KITE: 70.32 (-1.59), AZN: 32.94 (+0.13), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)

I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)

Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT

FIT: 44.66 (-0.81), PIRS: 3.12 (-0.08), KITE: 70.32 (-1.59), SRPT: 31.50 (-0.53), WSH: 46.60 (+0.41), CALA: 7.51 (-0.61), CLLS: 35.73 (-0.65), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), PNR: 60.63 (+1.18), APOL: 13.12 (-0.26), DSKX: 3.39 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading